AAM Calls Out Threat Of Consolidation Among Purchasers
Letter To Authorities Accuses Buying Groups And PBMs Of Anticompetitive Activities
Drug buying groups and pharmacy benefit managers are leaving generic drug producers unable to compete even when they have viable products due to concentration of buyer power, the Association for Accessible Medicines has highlighted.
You may also be interested in...
Remote inspection alternatives could allow quicker resolution of quality issues that are holding up US imports, says association for generic drug manufacturers. AAM adds that adjusting a Medicaid inflation penalty could relieve unfair price pressures.
The Inflation Reduction Act should take a different approach when it comes to authorized generic products, Sandoz US chief commercial officer Tim DeGavre has told Generics Bulletin.
A US Senate Finance Committee has heard divided opinions on the impact of vertical integration among pharmacy benefit managers, with one witness maintaining it may have positive competitive consequences while another condemned the practice outright.